Carna Biosciences Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 75

Employees

  • Stock Symbol
  • 4572

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.94
  • (As of Friday Closing)

Carna Biosciences General Information

Description

Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.

Contact Information

Website
www.carnabio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • BMA 3F 1-5-5 Minatojima-Minamimachi
  • Chuo-ku
  • Kobe, 650-0047
  • Japan
+81 000-000-0000
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
TKS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • BMA 3F 1-5-5 Minatojima-Minamimachi
  • Chuo-ku
  • Kobe, 650-0047
  • Japan
+81 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Carna Biosciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.94 $2.90 $1.96 - $5.86 $53M 18M 177K -$0.52

Carna Biosciences Financials Summary

In Thousands,
USD 		TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 21,529 41,756 29,922 95,661
Revenue 9,663 11,571 10,552 18,372
EBITDA (8,835) (7,771) (9,774) (4,640)
Net Income (9,130) (8,205) (10,269) (4,867)
Total Assets 22,904 30,844 32,539 47,211
Total Debt 549 1,297 2,291 4,692
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Carna Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Carna Biosciences‘s full profile, request access.

Request a free trial

Carna Biosciences Patents

  • 142

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 69

    Granted

  • 32

    Pending

  • 000

    Expiring in next 12 mo

Carna Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024017496-A Spiro derivative Pending 28-Jul-2022
JP-2023138470-A Pharmaceutical including amine derivative Pending 17-Mar-2022
JP-2023018839-A Pharmaceutical composed of novel alkyne derivative Pending 28-Jul-2021
US-20230097964-A1 Novel 1,2-diaminobenzimidazole derivative Active 21-Jul-2021 0000000000
CA-3226861-A1 Novel 1,2-diaminobenzimidazole derivative Pending 21-Jul-2021 C07D403/12
To view Carna Biosciences’s complete patent history, request access »

Carna Biosciences Executive Team (3)

Name Title Board Seat
Kohichiro Yoshino Ph.D Founder, President, Chief Executive Officer & Representative Director
Emi Yamamoto Chief Financial Officer, Director & President of CarnaBio
You’re viewing 2 of 3 executive team members. Get the full list »

Carna Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Carna Biosciences Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ProbeX 01-Oct-2013 0000000000 00.00 Other Healthcare Services
To view Carna Biosciences’s complete acquisitions history, request access »

Carna Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Laboratory Equipment and Services

Subindustry

Rank

Percentile

To view Carna Biosciences’s complete esg history, request access »

Carna Biosciences FAQs

  • When was Carna Biosciences founded?

    Carna Biosciences was founded in 2003.

  • Who is the founder of Carna Biosciences?

    Kohichiro Yoshino Ph.D is the founder of Carna Biosciences.

  • Who is the CEO of Carna Biosciences?

    Kohichiro Yoshino Ph.D is the CEO of Carna Biosciences.

  • Where is Carna Biosciences headquartered?

    Carna Biosciences is headquartered in Kobe, Japan.

  • What is the size of Carna Biosciences?

    Carna Biosciences has 75 total employees.

  • What industry is Carna Biosciences in?

    Carna Biosciences’s primary industry is Pharmaceuticals.

  • Is Carna Biosciences a private or public company?

    Carna Biosciences is a Public company.

  • What is Carna Biosciences’s stock symbol?

    The ticker symbol for Carna Biosciences is 4572.

  • What is the current stock price of Carna Biosciences?

    As of 13-Sep-2024 the stock price of Carna Biosciences is $2.94.

  • What is the current market cap of Carna Biosciences?

    The current market capitalization of Carna Biosciences is $53M.

  • What is Carna Biosciences’s current revenue?

    The trailing twelve month revenue for Carna Biosciences is $9.7M.

  • What is Carna Biosciences’s annual earnings per share (EPS)?

    Carna Biosciences’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »